Cognition Enhancers in Age-Related Cognitive Decline

@article{Riedel1996CognitionEI,
  title={Cognition Enhancers in Age-Related Cognitive Decline},
  author={Wim J. Riedel and Jelle Jolles},
  journal={Drugs \& Aging},
  year={1996},
  volume={8},
  pages={245-274}
}
SummaryA review of recently published studies on the effect of cognition enhancers in non-demented human study participants is presented. The heterogeneity of the therapeutic target, age-associated cognitive decline, can be improved by separately treating groups in whom age-extrinsic factors may underlie cognitive pathology. Standardisation of cognitive assessments is necessary, since many different tests are applied to answer the same question. Modelling cognitive dysfunction, either by… 
Nutrients, age and cognition.
TLDR
The importance of the need to start bridging the gap between disciplines by identifying possible human experimental models of altered cognitive function, which can elucidate the specific mechanisms of action through which nutritional supplements may enhance cognitive performance in humans in vivo, is stressed.
Impaired cognition and attention in adults: pharmacological management strategies
TLDR
“Drug therapeutic strategies” for improving cognition (except for memory function) are currently rather scarce, but promising perspectives for a new neurobiological approach to cognitive pharmacology will be highlighted.
Treatment of mild cognitive impairment: rationale, present and future strategies
TLDR
Currently available symptomatic treatments with acetylcholinesterase inhibitors, putative treatments such as antiglutamatergic drugs, nootropics, antioxidants, anti‐inflammatory drugs and still controversial estrogen replacement therapy, and visionary treatments targeting neuropathological substrates of the disease are reviewed.
Age-Associated Memory Impairment
TLDR
More reliable diagnostic approaches are needed for use in studies that are attempting to identify the risk factors for dementia or to find a treatment for very early dementia, as AAMI appears to occur in a highly heterogeneous group of individuals.
The Influence of Soy-derived Phosphatidylserine on Cognition in Age-Associated Memory Impairment
TLDR
A daily supplement of S-PS does not affect memory or other cognitive functions in older individuals with memory complaints, and there were no significant interactions between treatment and ‘severity of memory complaints’.
Issues in pharmacopsychology : modeling effects in driving and cognition
This thesis deals with side effects of medicinal drugs on behaviour from a pharmacopsychological perspective. Because it focuses on behaviour and not on the drug itself, a much more refined study of
Lifestyle factors and cognitive ageing in the Lothian Birth Cohort 1936: exploring the role of confounding by prior cognitive ability
TLDR
The positive and significant associations observed between ‘healthy’ lifestyle factors and better cognitive functions at age 70 were consistent with previous research; their effect size was around 1% of the variance in cognitive tests scores.
Therapeutic approaches to age-associated neurocognitive disorders
TLDR
The present article aims to provide an overview of the most current therapeutic approaches to age-associated neurocognitive disorders and discusses the conceptual and methodological issues that surround the design, implementation, and interpretation of such approaches.
Cognitive Impairment in Elderly People
TLDR
Current views on the borderline between normal and pathological cognitive aging are reviewed, with a view to treating symptoms of cognitive dysfunction on the basis of diagnosis of health-related factors, in age-related cognitive decline and depression.
...
...

References

SHOWING 1-10 OF 166 REFERENCES
Early human trials in the assessment of cognition activators.
TLDR
The assessment of cognition enhancers in the clinic is a broad topic that can be addressed from both academic/theoretical and therapeutic/drug development perspectives and it is necessary to utilize larger numbers of subjects and longer-term studies.
Late clinical testing of cognition enhancers: demonstration of efficacy.
TLDR
Clinical trials of cognition enhancers, for example in senile dementia, require at least 6 months and parallel group designs seem preferable and the so-called "enriched design" seems to possess advantages over more classical procedures.
Age-Related Effects of the Nicotinic Antagonist Mecamylamine on Cognition and Behavior
TLDR
The results indicate that acute blockade of nicotinic receptor function can produce measurable and significant cognitive impairment similar to some deficits seen in dementing illnesses, and that there is an age-related increase in sensitivity to Nicotinic blockade.
Early clinical testing of cognition enhancers: prediction of efficacy.
TLDR
It was suggested that some human models (e.g. scopolamine-induced amnesia, hypoxia-induced performance deficits) were indeed potential predictors of clinical response and, in addition, were analogous to similar models in animals.
Memory disorders: novel treatments, clinical perspective.
  • G. Pepeu
  • Psychology, Medicine
    Life sciences
  • 1994
Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia
TLDR
Results show that moclobemide may improve cognition in conditions associated with cholinergic deficit, and may therefore be especially indicated in the treatment of cognitive decline occurring with normal aging, depression in elderly people and Alzheimer's disease.
Age‐associated memory impairment
TLDR
A role for catecholamines is proposed in AAMI and possible treatment strategies are discussed, as in studies of dementia, as much attention is focused on cholinergic function in relation to AAMI, with less emphasis on other neurochemical systems, such as those containing catechols.
[Epidemiologic study on the effectiveness and safety of dihydroergocristine in impaired memory and behavioral functions in aged humans].
TLDR
Analysis of results demonstrated that at the end of the study responsivity was high in 73% of cases, moderate in 20.4% and absent in 6.5%.
The cholinergic hypothesis of geriatric memory dysfunction.
Biochemical, electrophysiological, and pharmacological evidence supporting a role for cholinergic dysfunction in age-related memory disturbances is critically reviewed. An attempt has been made to
Effects of phosphatidylserine in age‐associated memory impairment
TLDR
Analysis of clinical subgroups suggested that persons within the sample who performed at a relatively low level prior to treatment were most likely to respond to BC‐PS, and there was improvement on both computerized and standard neuropsychological performance tests, and on clinical global ratings of improvement.
...
...